Amgen, Inc. (NASDAQ:AMGN)

research

Biotech Short Sellers Run for Cover

The short interest data are out for the most recent settlement date, December 30. Generally speaking, companies within the biotech industry are considered to have a riskier group of stocks, ...
Read Full Story »
Good heart health

Friday’s 6 Biopharma Movers That Can’t Be Ignored

There is a very positive sentiment in the health care sector considering the new Trump administration that will be taking over in just two weeks. The health care sector was ...
Read Full Story »
biotech word cloud

Biotech Short Interest Sinks

The short interest data are out for the most recent settlement date, December 15. Generally speaking, companies within the biotech industry are considered to have a riskier group of stocks, ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Amgen, American Express, American Water Works, Celgene, Square and More

Stocks hit all-time highs last week, but the Dow Jones Industrial Average remained about 100 points under the elusive 20,000 mark on Tuesday. As 2016 comes to an end, the ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Amgen, Coca-Cola, IBM, Procter & Gamble, Viacom, SeaWorld, NovoCure and More

Stocks were mixed on Monday, with the Dow up and the Nasdaq and S&P 500 lower. Those same indexes were indicated higher on Tuesday, and the Dow is getting ever closer ...
Read Full Story »
biotech word cloud

Biotech Short Interest Remains Mixed

The short interest data are out for the most recent settlement date, November 30. Generally speaking, companies within the biotech industry are considered to have a riskier group of stocks, ...
Read Full Story »
biotech word cloud

Short Sellers Grow More Aggressive on Major Biotechs

The short interest data are out for the most recent settlement date, November 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
upside

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

If any sector has had a tough go of it the past year, it has been health care, and especially biotechnology. Continued harsh rhetoric from politicians, especially the Democrats, over ...
Read Full Story »
biotech word cloud

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
hammered

6 Companies That Destroyed Shareholders Last Week

The broad markets are holding steady near their double bottom set this summer. However, over the course of the past week this has been tested. Quite a few companies were ...
Read Full Story »
coins

Amgen Sinks Despite Beating Street Estimates

When Amgen Inc. (NASDAQ: AMGN) reported its third-quarter financial results after the markets closed on Thursday, the company said that it had $3.02 in earnings per share (EPS) and $5.81 ...
Read Full Story »
Female patient on gurney

What to Watch When Amgen Reports Earnings

Amgen Inc. (NASDAQ: AMGN) is scheduled to release its third-quarter financial results after the markets close on Thursday. Consensus estimates from Thomson Reuters call for $2.79 in earnings per share ...
Read Full Story »
biotech word cloud

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The short interest data are out for the most recent settlement date, October 14. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
biotech word cloud

Top Health Care Earnings Coming Next Week

Earnings season is now in full swing, and we have put together a preview of some of the world’s largest players in the health care sector. This current quarter ahead ...
Read Full Story »
Pills and tablets

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

It is no secret that the health care system in America needs help. Treatment costs have gone through the roof over the past two decades, and there is an ongoing ...
Read Full Story »